The world is facing an enormous supply crisis.
That means that as you go about your daily business, you need to buy the most effective medication possible.
That’s where pharmacies come in.
The NHS has been providing drugs and supplies to pharmacies since it was founded in 1796.
Today, the UK’s largest pharmacy chain, Pharmacy Benefits Group, has about 7,000 pharmacies in its network.
Its pharmacies are the world’s most valuable.
But pharmacy benefits groups have to compete with the competition, with competitors often charging higher prices than their competitors.
And they often take a cut of that profit.
This has led to a supply glut.
In 2015, there were almost a quarter of a million pharmacies in the UK, with fewer than 400 of them able to compete.
The NHS has invested in a number of ways to try to solve this, but the most important is a drug-manufacturing programme that it began in 2014 with the £100 million Medicines and Healthcare products Scheme.
This scheme is now a major part of the NHS budget.
It aims to develop innovative medicines, which can be sold at competitive prices.
The aim is to cut down on the costs of medicines, but there is a catch.
The scheme is designed to be a short-term solution, and it won’t have any effect on the number of medicines being manufactured.
This means that the scheme will eventually lead to the end of the supply glut, and a sharp rise in prices.
But if the NHS can’t keep up with the demand, the supply will fall.
In response, the government introduced the Medicines for Life scheme in 2016, which aims to build a network of new, more effective medicines for the NHS.
This scheme is similar to the one that the NHS launched in 2014, with a different target: to reduce the amount of time people spend on medicines.
As the programme is currently set, the NHS says it can supply about 30 new medicines per year, which will keep the glut in check.
The Government has invested £2.3 billion over the next three years into the scheme, but its success will depend on whether the drugs actually make it to market.
How much does it cost to make a new drug?
If the medicines that the government wants to develop are effective, then they need to be cheaper than the current generic drugs.
For most medicines, this is a very straightforward task.
A company makes a new, safer version of a drug and then sells it for a fixed price.
It is possible to make cheap generic versions of these drugs.
But for most medicines the price is more complicated.
Some medicines are more expensive to make than others, or have higher manufacturing costs.
These differences are called generics.
Generic drugs are designed to treat specific conditions or diseases, while their cheaper counterparts are designed for the wider market.
These cheaper versions of the same drug will also often have higher generic competition than the cheaper generic versions, so the price will have to fall.
If the generic drugs aren’t competitive enough, then the government can introduce new generic versions.
These new generics have different manufacturing costs, so they will need to compete for the same patients as the cheaper generics do.
If that’s not possible, then some manufacturers will make their own versions.
Some generics are cheaper to make, but are less effective than the generic versions that the manufacturers have.
If these new versions don’t meet the NHS’s requirements, then there is the option of switching to the cheaper versions.
That option is known as “retail”, because the generic version of the drug will be sold as an NHS-approved version.
But it can be costly, and the cost of this could easily be the difference between getting the cheapest generic version and getting a new version of an older drug.
How will the NHS solve the supply problem?
The government’s current plan is to develop new generasics.
It says that once the new generaics are approved, it will continue to develop them and make them more effective, so that the number and quality of new medicines produced will be higher.
But there is one problem.
In order to develop a new generic, there needs to be sufficient supply.
In practice, the problem is that most medicines can be bought in supermarkets, which are expensive to run.
In that case, a cheaper generic version will probably have to be used to replace the cheaper version.
That is where the government’s Pharmaceutical Benefits Scheme comes in.
It’s designed to tackle this by providing the NHS with a network that will sell generic versions and to make the new versions available to the wider NHS.
It has so far invested £600 million in the scheme so far, and has plans to spend another £200 million over the course of the year.
But the programme’s most important objective is to get the cheapest medicines into the hands of the most vulnerable patients.
What are the biggest problems in the pharmaceutical industry? The